Italia markets closed

Krystal Biotech, Inc. (KRYS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
177,93+0,73 (+0,41%)
Alla chiusura: 04:00PM EDT
177,93 0,00 (0,00%)
Dopo ore: 04:08PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente177,20
Aperto176,49
Denaro177,67 x 100
Lettera178,67 x 200
Min-Max giorno175,99 - 180,12
Intervallo di 52 settimane77,10 - 189,97
Volume384.185
Media Volume397.650
Capitalizzazione5,034B
Beta (5 anni mensile)0,86
Rapporto PE (ttm)456,23
EPS (ttm)0,39
Prossima data utili06 mag 2024 - 10 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A185,90
  • GlobeNewswire

    Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

    PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the Company will participate in the Chardan 7th Annual Genetic Medicines Conference in New York. Krish Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conferenc

  • GlobeNewswire

    Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

    • Orphan Drug Designation Granted to KB408 PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug Application (IND) for KB408 for the treatment of alpha-1 antitrypsin deficiency (A

  • GlobeNewswire

    Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

    PITTSBURGH, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced today that the Company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York. Krish Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the c